LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Thermo Fisher Launches CE-IVD Marked Next-Generation TaqPath COVID-19 RNase P 2.0 Assay Kit

By LabMedica International staff writers
Posted on 27 Oct 2021
TaqPath COVID-19 RNase P 2.0 kit
TaqPath COVID-19 RNase P 2.0 kit
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the CE-IVD marked TaqPath COVID-19 RNase P 2.0 kit, a newly designed test that provides accurate results by compensating for current and future COVID-19 viral mutations.

The kit has been redesigned to detect active SARS-CoV-2 infections by identifying the presence of any one of eight gene targets from the virus. By surveying across multiple genes, the test can net accurate results even as mutations shift the genes they express. The TaqPath COVID-19 RNase P 2.0 kit uses an RNase P control to ensure sample integrity, quality and extraction.

The TaqPath COVID-19 RNase P 2.0 kit uses a newly designed assay to assess nasopharyngeal and nasal swab samples to detect active COVID-19 cases. The test has a turnaround time of about three hours. The first-generation test, TaqPath COVID-19 CE-IVD RT PCR Kit, has been available with a CE-IVD mark since March 2020.

"SARS-CoV-2 is continuing to mutate, and this assay is the latest in our efforts to make sure our tests are future proofed against those variants," said Manoj Gandhi, senior medical director for genetic testing solutions, Thermo Fisher Scientific. "With this product, we are offering customers the next generation of our COVID-19 diagnostic test that has inbuilt checks and balances in the face of emerging variants."

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Clinical Chemistry System
P780

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
GLOBE SCIENTIFIC, LLC